Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors (Q37132720)

18 August 2017

1 reference

title

Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors (English)

1 reference

stem cell transplantation

18 August 2017

main subject

1 reference

7

Jacques-Olivier Bay

1 reference

18 August 2017

11

Dietger Niederwieser

1 reference

18 August 2017

3

Didier Blaise

1 reference

18 August 2017

8

Fikret Arpaci

1 reference

18 August 2017

Taner Demirer

1

1 reference

18 August 2017

Lisbeth Barkholt

2

1 reference

18 August 2017

Paolo Pedrazzoli

4

1 reference

18 August 2017

Massimo Aglietta

5

1 reference

18 August 2017

Angelo Michele Carella

6

1 reference

18 August 2017

Giovanni Rosti

9

1 reference

18 August 2017

Gunhan Gurman

10

1 reference

18 August 2017

Marco Bregni

12

1 reference

18 August 2017

EBMT Solid Tumors Working Party

13

1 reference

18 August 2017

publication date

8 April 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

256-267

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc1104

18 August 2017

exact match

0 references

cites work

Hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Immune recognition of a human renal cancer antigen through post-translational protein splicing.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC1104

1 reference

7 January 2021

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Immunotherapy for advanced renal cell cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

The second international meeting on allogeneic transplantation in solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Tumor-infiltrating T cells--friend or foe of neoplastic cells?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Inhibition of experimental and spontaneous lung metastases of highly metastatic Syrian hamster sarcoma cells by non-activated bone marrow and peritoneal exudate cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Safety of retroviral gene marking with a truncated NGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1104

7 January 2021

Identifiers

DOI

10.1038/NCPONC1104

1 reference

Dimensions Publication ID

18 August 2017

1010410430

0 references

1 reference